Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
BUSINESS
Court’s Settlement Offer on Opdivo Royalty Dispute Fails
The Osaka District Court on April 27 made a settlement offer for Ono Pharmaceutical and Kyoto University Prof. Tasuku Honjo in their IP royalty dispute over the anti-PD-1 antibody Opdivo (nivolumab), but talks ended in a rupture with both sides…
To read the full story
Related Article
- Ono to Pay 28 Billion Yen to Settle Opdivo Feud with Honjo
November 15, 2021
- Ono, Honjo to Continue Settlement Discussions in Opdivo Royalty Feud
September 24, 2021
- Court Pitches Settlement in Opdivo Royalty Row, Response Due Sept. 22
September 13, 2021
- Ono Chief, Honjo Remain Divided over Opdivo Royalty in Direct Face-Off
September 3, 2021
- Honjo Ups Royalty Claim after Tecentriq Settlement: Opdivo Row
June 14, 2021
- Ono, Prof. Honjo Disagree About Validity of Patent Royalty Rate for Opdivo
January 6, 2021
- Ono Says Honjo’s 22.6 billion Yen Claim Groundless, No Agreement Reached on 40% Opdivo Fee Proposal
October 27, 2020
- Ono to Fight Prof. Honjo’s Lawsuit over Opdivo Royalties
July 7, 2020
- Nobel Laureate Honjo Sues Ono over Opdivo Royalties, Demands 22.6 Billion Yen
June 22, 2020
- Ono President Confident of Validity of Company’s Argument on Opdivo Royalties
June 19, 2020
- Nobel Laureate Honjo Taking Ono to Court, Demands 22.6 Billion Yen
June 8, 2020
- Royalty Feud with Nobel Laureate Takes Center Stage at Ono Shareholder Meeting
June 21, 2019
- Ono Offers Its Account of License Fee Row with Nobel Laureate
May 23, 2019
- I/O Pioneers Win Nobel Prize in Medicine; Honjo Prods Japan Firms to Make More Academic Investment at Home
October 2, 2018
BUSINESS
- Takeda Puts Up 100 Billion Yen for New Plasma Therapy Facility in Japan
March 24, 2023
- Ono, Kasawaki-Based AI Platform Firm Tie Up on Antibody Drug Discovery
March 24, 2023
- Hutchmed’s Colorectal Cancer Med Logs Positive Data in Japanese Cohort: Takeda
March 24, 2023
- Ono, Macomics Ink Macrophage Drug Discovery Deal
March 24, 2023
- Opdivo Gets South Korea OK for 1st Line Esophageal Cancer
March 24, 2023
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…